|
EID Parry completes
acquisition of Valensa
- Chennai, October 4, 2011: E.I.D.-Parry
(India) Limited, a part of the USD 3.8 billion Murugappa
Group, has announced acquisition of 100% of the voting shares
of U. S. Nutraceuticals LLC (Valensa International), a Limited
Liability Company based in Florida, USA
Parry acquired a 48% stake in
Valensa in 2008 as a part of its business strategy to move up the
value chain in the Nutraceuticals Business. Valensa International is
a leading science-based developer and provider of high quality
nature-sourced ingredients and formulations for nutritional
supplements and functional super foods with its certified organic
production facilities located in a protected pine forest and Saw
palmetto grove in Orlando, Florida. Valensa offers a range of
branded ingredients and innovative formulations including
Astaxanthin, Spirulina & Astaxanthin Complex, Saw Palmetto
Extracts, Perilla seed CO2 extract, CO2 Chia Seed Extract, Chia Seed
Oil, Low-Fat Whole Grain, Cranberry Seed Extract, Astaxanthin-Cranberry
Seed Extract and its new formulated Krill product.
“There is a huge synergy in this
acquisition” said Mr. Sajiv Menon, Business Head (Bio &
Nutraceuticals) of E.I.D.-Parry. He added “Parry Nutraceuticals is
a global leader in micro algal technology producing the world’s
finest certified organic Spirulina, natural beta carotene from
Dunaliella salina, and Astaxanthin from Haematococcus pluvialis. We
have our manufacturing facilities in Tamil Nadu and in Maharashtra
and apart from the algal products also produce and market Lycopene
from Tomato paste and have recently launched Galactomannan, a
soluble fibre extracted from Fenugreek known to have major benefits
in diabetes management. We have also entered the Indian OTC market
with the launch of Pro9, a whey based Protein drink powder and Pro9D
a protein drink with Fenugreek extracts for diabetics, with many
more products in the pipeline. Parry has established itself as a
producer of high quality ingredients like Organic Spirulina over the
last fifteen years with customers in Europe, the US and Asia. This
acquisition provides the platform for Parry to move up the value
chain by manufacturing value added formulations from its ingredients
apart from cross selling opportunities in the US and in the rest of
the world for both Parry and Valensa”.
“Valensa’s Pur Blue SpiruZan
tablets are the first product of its type that appeals to the
finicky consumer who is looking for a taste enhanced algal product
and we have developed this together with Parry as an example of
the cooperation between the two companies” said Dr. Rudi E.
Moerck CEO of Valensa. “This is a great way for Americans to
benefit from a nutritious ‘green’ Spirulina algae product
without that typical algae taste. Valensa’s business is now
poised to take off with the company developing science based
condition specific formulated products that address unmet needs in
Joint Health, Aging, Men’s and Women’s Health as well as
advanced Astaxanthin containing formulations for Eye Health. In
the area of Eye Health, Valensa holds a key patent on the use of
Astaxanthin which generally mitigates the damaging effects of UV
and oxidative stress on the eye, a worldwide problem” he added.
“Valensa has developed new
clinically trialed formulated products for Joint Health based on
Krill oil and key Valensa ingredients such as Astaxanthin. This
flagship product, FlexPro MD™, will be marketed by leading
companies under their own brand names in the US. The product is a
small one-a-day softgel that does not contain chondroitin nor
glucosamine and has been shown to be highly effective in clinical
trials and has now been licensed to major marketers in the Mass,
Food and Drug as well as the Catalogue, Internet and Natural
Products Marketplace”, said Mr. Menon of Parry. Dr. Moerck added
that “there will be significant launches of Valensa’s
formulated products by key marketers in the fourth Quarter and Q1
of 2012.”
Parry invested Rs.22.4 crores for
acquisition of the outstanding shares of Valensa.
About Murugappa Group
Founded in 1900, the Rs. 17051
Crores (USD 3.8 billion) Murugappa Group is one of India's leading
business conglomerates. The Group has 29 businesses including eight
listed Companies actively traded in NSE & BSE. Headquartered in
Chennai, the major Companies of the Group include Carborundum
Universal Ltd., Cholamandalam Investment and Finance Company Ltd.,
Cholamandalam MS General Insurance Company Ltd., Coromandel
International Ltd., Coromandel Engineering Company Ltd., E.I.D.
Parry (India) Ltd., Parry Agro Industries Ltd., Tube Investments of
India Ltd. and Wendt (India) Ltd.
Market leaders in served segments
including Abrasives, Auto Components, Cycles, Sugar, Farm Inputs,
Fertilizers, Plantations, Construction, Bio-products and
Nutraceuticals, the Group has forged strong joint venture alliances
with leading international companies like Groupe Chimique Tunisien,
Foskor, Cargill, Mitsui Sumitomo and Morgan Crucible. The Group has
a wide geographical presence spanning 13 states in India and 5
continents. Renowned brands like BSA, Hercules, Ballmaster, Ajax,
Parry’s, Gromor and Paramfos are from the Murugappa stable. The
organization fosters an environment of professionalism and has a
workforce of over 32,000 employees.
For further queries, contact
Vinod Kumar/Diya Kinger,
Ogilvy Public Relations Worldwide
Mobile : 9840126179/ 8939623044
R V Prasad,
External Communications Lead,
Murugappa Group.
Mobile : 9840120590
Top
|